Controlled release of antigen and Toll-like receptor ligands from PLGA nanoparticles enhances immunogenicity. (March 2017)

• Record Type: Journal Article
• Authors: Cruz, Luis J; Tacken, Paul J; Eich, Christina; Rueda, Felix; Torensma, Ruurd; Figdor, Carl G
• Is Part Of: Nanomedicine. Volume 12:Number 5(2017)
• Page Start: 491
• Page End: 510
• Publication Date: 2017-03
• Subjects: biocompatible materials -- dendritic cells -- fluorescence -- nanoparticles; Nanotechnology -- Periodicals; Medical technology -- Periodicals; Nanotechnology -- Therapeutic use -- Periodicals; 610.28
• DOI: 10.2217/nnm-2016-0295
• Languages: English
• ISSNs: 1743-5889

Abstract

Aim: Dendritic cells rapidly capture nanoparticles and induce a potent cellular immune response. It is yet unknown whether the immunological response induced by slow release of encapsulated versus soluble antigen and adjuvant is superior.Materials & methods: The kinetics of poly(lactic-co-glycolic acid) PLGA nanoparticles antigen release was studied by the DQ-bovine serum albumin (BSA) self-quenching antigen model. The immunological response induced was evaluated by means of dendritic cell activation/maturation markers, cytokine production and their ability to drive antigen-specific T-cell proliferation.Results & conclusion: PLGA-encapsulated antigen and adjuvant showed an enhanced T-cell response when compared with soluble vaccine components by increasing antigenicity and adjuvanticity. Although the kinetic profile followed the same pattern, encapsulation increased strength and duration of the response. Graphical Abstract: